DiaPep277 meets Phase III endpoint

Andromeda Biotech Ltd. said subcutaneous DiaPep277 plus insulin therapy met the primary endpoint of preserving C-peptide levels from baseline to 24 months vs. insulin therapy alone in the Phase III DIA-AID trial to treat newly diagnosed Type I diabetes. Data were from 388 patients in the modified intent-to-treat (mITT) population, which included patients who received at least one dose of study medication and at least one measurement post-baseline. ...